We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

48 hedge funds and large institutions have $136M invested in VanEck Pharmaceutical ETF in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 17 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more capital invested

Capital invested by funds: $71M → $136M (+$65.2M)

31.01% more ownership

Funds ownership: 24.58% → 55.6% (+31%)

0% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 5

4% less funds holding

Funds holding: 50 → 48 (-2)

30% less call options, than puts

Call options by funds: $312K | Put options by funds: $445K

35% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 17

Holders
48
Holders Change
-2
Holders Change %
-4%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
11
Reduced
17
Closed
5
Calls
$312K
Puts
$445K
Net Calls
-$133K
Net Calls Change
+$180K

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$65.3M
2
SG Americas Securities
SG Americas Securities
New York
+$5.68M
3
BCI
Brinker Capital Investments
Pennsylvania
+$1.25M
4
UBS Group
UBS Group
Switzerland
+$848K
5
WI
Wintrust Investments
Illinois
+$429K

Top Sellers

Rank Fund Capital Flow
1
RJFSA
Raymond James Financial Services Advisors
Florida
-$2.43M
2
SCM
Stuyvesant Capital Management
New York
-$1.62M
3
TRCT
Tower Research Capital (TRC)
New York
-$915K
4
SB
Suntrust Banks
Georgia
-$696K
5
VF
Virtu Financial
New York
-$572K
Name Holding Trade Value Shares
Change 		Change in
Stake
LTFS
26
Ladenburg Thalmann Financial Services
Florida
$196K -$77.5K -1,365 -29%
Bank of Montreal
27
Bank of Montreal
Ontario, Canada
$173K +$8.18K +144 +5%
FDCDDQ
28
Federation des caisses Desjardins du Quebec
Quebec, Canada
$139K – – –
JP Morgan Chase
29
JP Morgan Chase
New York
$123K -$8.52K -150 -7%
TCM
30
Tradewinds Capital Management
Washington
$69K – – –
MA
31
MUFG Americas
New York
$61K – – –
GT
32
Glenmede Trust
Pennsylvania
$57K – – –
ASN
33
Advisory Services Network
Georgia
$50K +$57 +1 +0.1%
MIM
34
Macroview Investment Management
Maryland
$44K +$57 +1 +0.1%
HCM
35
Highlander Capital Management
New Jersey
$43K -$19.9K -350 -32%
NSIM
36
North Star Investment Management
Illinois
$34K +$114 +2 +0.3%
TRCT
37
Tower Research Capital (TRC)
New York
$27K -$915K -16,116 -97%
Carson Wealth (CWM LLC)
38
Carson Wealth (CWM LLC)
Nebraska
$23K – – –
WWM
39
Willingdon Wealth Management
North Carolina
$19K +$19.1K +336 New
CPA
40
Clear Perspective Advisors
Illinois
$17K – – –
EDRH
41
Edmond de Rothschild Holding
Switzerland
$12K -$11.4K -200 -50%
ADL
42
Asset Dedication LLC
California
$10K – – –
IA
43
IFP Advisors
Florida
$9K – – –
FANJ
44
Financial Architects (New Jersey)
New Jersey
$4K – – –
JCM
45
Jacobi Capital Management
Pennsylvania
$3K – – –
AG
46
Advisor Group
Arizona
$1K -$1.42K -25 -58%
BFEC
47
Benjamin F. Edwards & Company
Missouri
$1K – – –
SCM
48
Stuyvesant Capital Management
New York
– -$1.62M -27,420 Closed
SB
49
Suntrust Banks
Georgia
– -$696K -11,916 Closed
FPCM
50
Financial Partners Capital Management
New York
– -$201K -3,409 Closed
1
2
3

PPH Hedge Fund Activity: Q3 2017 in Review

48 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q3 2017, worth a combined $136M — up 92% from $71M a quarter earlier.

Fund positioning in PPH was balanced in Q3 2017: 5 funds opened new positions, 5 closed out, 11 added to existing stakes and 17 trimmed.

The largest buyer was Bank of America, adding an estimated $65.3M. The largest seller was Raymond James Financial Services Advisors, cutting an estimated $2.43M.

  • 48 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q3 2017, down from 50 in Q2 2017.
  • Funds reported $136M of VanEck Pharmaceutical ETF stock for Q3 2017, up 92% quarter-over-quarter.
  • 5 funds opened new VanEck Pharmaceutical ETF positions in Q3 2017 and 5 closed out, a net change of 0 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q3 2017 was Bank of America, an estimated $65.3M added.
  • The largest VanEck Pharmaceutical ETF seller in Q3 2017 was Raymond James Financial Services Advisors, an estimated $2.43M sold.

Based on aggregated 13F filings for Q3 2017.